Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
PHASE3CompletedINTERVENTIONAL
Enrollment
19
Participants
Timeline
Start Date
May 31, 2012
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
Conditions
Cardiovascular Abnormalities
Interventions
DRUG
Sirolimus
Trial Locations (1)
1200
Cliniques universitaires Saint-Luc, Brussels
All Listed Sponsors
lead
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
NCT01811667 - Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations | Biotech Hunter | Biotech Hunter